Kohjin Bio Co., Ltd. Logo

Kohjin Bio Co., Ltd.

A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.

177A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
坂戸市千代田5−1−3
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development, manufacture, and sale of products for life sciences research and clinical applications. Its core offerings include tissue and cell culture media, media for microbial testing, and in-vitro diagnostic reagents. The company also provides animal-derived biological materials such as blood and serum. A key area of focus is regenerative medicine and cell therapy, where Kohjin Bio operates as a leading Contract Development and Manufacturing Organization (CDMO) in Japan, producing specialized culture media. Additionally, the company offers bioservices, including immunology contracts and the processing of cells for cancer immune therapies through partnerships with medical institutions.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Kohjin Bio Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 08:30
Regulatory News Service
臨時報告書
Japanese 23.8 KB
2025-06-24 09:09
Regulatory News Service
内部統制報告書-第44期(2024/04/01-2025/03/31)
Japanese 25.0 KB
2025-06-24 09:08
Regulatory News Service
確認書
Japanese 9.0 KB
2025-06-24 09:06
Annual Report
有価証券報告書-第44期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2024-11-14 07:30
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:30
Interim Report
半期報告書-第44期(2024/04/01-2025/03/31)
Japanese 200.4 KB
2024-07-04 02:15
Regulatory News Service
臨時報告書
Japanese 27.7 KB
2024-06-28 08:09
Regulatory News Service
確認書
Japanese 9.0 KB
2024-06-28 08:00
Annual Report
有価証券報告書-第43期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-04-25 05:44
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2024-04-16 08:01
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-04-08 03:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-03-22 07:00
Prospectus
有価証券届出書(新規公開時)
Japanese 3.5 MB

Automate Your Workflow. Get a real-time feed of all Kohjin Bio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Kohjin Bio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.